Emerging Treatments and Novel Modalities in Head and Neck Cancers

Mortality and morbidity rates remain high in head and neck cancer (HNC). Novel radiopharmaceuticals, injectable therapies, advances in systemic therapy, including novel immunomodulators and cell-based therapies, and system-level changes to address widening global disparities are promising contemporary avenues. Advances are clearly needed to improve outcomes in this disease, but equally important is implementation that maximizes clinical benefit for common and unique subtypes and addresses needs at a global level. HNC remains an active area of investigation where therapeutic innovations are driving new challenges and opportunities.